NCT03707028 2022-04-11A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction CancerElevar TherapeuticsPhase 1/2 Terminated12 enrolled